Merck + Co., Inc.

Gerald F Bills

Fernando Pelaez

Deborah L Zink

Maria T Diez

James E Curotto

John R Thompson

Francisca Vicente

Robert E Schwartz

Robert A Giacobbe

Sheo B Singh

Jerrold M Liesch

Anne W Dombrowski

Sandra A Morris

Otto D Hensens

Janet C Onishi

Russell B Lingham

Angela Basilio

Sarah J Dreikorn

Keith C Silverman

Suzanne M Mandala

Mary N Omstead

Jon David Polishook

Rosemary A Thornton

Maria S Meinz

Stanley L Streicher

Rosalind G Jenkins

Fernando Pelaez Perez

Angeles Cabello Arroyo

Michael A Goetz

Guy H Harris

Sandra J Rattray

Wendy S Horn

Joyce A Greene

Angeles Cabello

Richard K Jansson

Wendy H Clapp

Gary K Darland

Isabella Martin

Christine Lange Cannova

Evon A Bolessa

Isabel Martin Fernandez

Teresa Diez Matas

Francisca Vicente Perez

Seok H Lee

Michel M Chartrain

Dennis M Schmatz

Leeyuan Huang

Ali Shafiee

Daniel Richard Sidler

Isabel Martin

John G Ondeyka

Colleen S Taylor

Jon D Polishook

Norihiro Ikemoto

Lawrence R Koupal

Jack L Smith

Gregory L Helms

Hans E Huber

Christopher Roberge

Ana M Teran

Myra B Kurtz

Gino M Salituro

Teresa D Matas

Michael J Salvatore, Jr

Bei B Zhang

Mark Rattray

Bruce W Burgess

Denis R Patrick

S Dreikorn

Marie Williams

Sarah J Driekorn

M Dolores Vilella Amils

Marina Mojena Sanchez

Annie Z Zhao

Julian Gorrochategui

Barnali Pramanik

Royo Inmaculada

Francisca Vincente Perez

Susan L Raghoobar

Russel B Lingham

Teresa Diez

Disclosed is a method for controlling phytopathogenic fungi using pure strains of ATCC 74386 and fungus ATCC 74387. Further, methods of producing a sordarin compound are disclosed. The method includes cultivating each strain separately in a nutrient medium containing assimilable sources of carbon and nitrogen and recovering the compound. A sordarin compound of formula I is also disclosed. Also an antifungal composition containing a sordarin compound is also disclosed.

Rosellinia subiculata ATCC 74386 and fungus ATCC 74387 for producing sordarin compounds for fungi control

Natural products such as certain chaetochromins are described. These compounds are useful in the inhibition of HIV integrase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

HIV integrase inhibitors

This invention relates to crystalline pharmaceutically acceptable salts of an alpha 1a adrenergic receptor antagonist, Compound A, which are useful in the treatment of benign prostatic hyperplasia. Pharmaceutical compositions employing the crystalline salts, and processes for making and using the crystalline salts and pharmaceutical compositions of Compound A are also disclosed. This invention further relates to a process for obtaining enantiomerically pure intermediate useful for the synthesis of end product alpha 1a adrenergic receptor antagonists. The end product compounds are useful for the treatment of benign prostatic hyperplasia and for relaxing lower urinary tract tissue. The invention also relates to a process for preparing a class of dihydropyrimidinone compounds of which Compound A is a member, wherein the process involves deprotonating a dihydropyrimidinone compound and then coupling the deprotonated derivative with a primary amine.

Enzymatic process of making alpha 1a adrenergic receptor antagonists using protease

Indolylquinones are useful for the treatment and prevention of diabetes mellitus, and in particular, for the treatment or prevention of hyperglycemia in diabetic patients. Some of the indolylquinones are produced by fermentation of the novel fungus Pseudomassaria sp. ATCC 74411.

Indolylquinones as antidiabetic agents

A compound represented by the formula I is disclosed: ##STR1## or a pharmaceutically acceptable salt or hydrate thereof. The compound has inhibitory activity against the oncoprotein Raf. Also included are pharmaceutical compositions, methods of treating cancer, cultures of the producing fungal microorganism and methods of fermentative production of the compound.

Bis-aryl ethers, compositions containing such compounds and methods of

The present invention provides novel cyclic tetrapeptides useful in the treatment or prevention of protozoal diseases; in particular, the novel compounds are active against the causative pathogens in malaria, toxoplasmosis, and coccidiosis.

Antiprotozoal cyclic tetrapeptides

There are disclosed novel compounds having the formula ##STR1## which exhibit antifungal activity.

Antifungal agents

There is disclosed a novel compound having the formula ##STR1## which exhibits antifungal activity.

Antifungal agent obtained from hormonema

Antifungal agent

There is disclosed a compound having the formula ##STR1## which is produced by the fungus, Arthrinium arundinis ATCC 74359, and exhibits antifungal activity.

Antifungal agent produced by arthrinium arundinis  ATCC 74359

A compound having the formula ##STR1## which is an anti-fungal agent is described. The producing organism Colletotricum accutatum is also described, along with a method of production.

Anti-fungal agents

Growing community of inventors

Clark, NJ, United States of America

Gerald F Bills